Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge

Simply Wall St

Tue, February 17, 2026 at 9:22 AM GMT+9 5 min read

In this article:

CRVS

-0.53%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

If you are wondering whether Corvus Pharmaceuticals' recent share price puts it on your watchlist or your worry list, you are not alone.

The stock last closed at US$18.66 after a 131.8% return over 30 days, a 154.9% return year to date, a 282.4% return over 1 year and a very large 3 year return, followed by a 7 day return of an 8.6% decline.

Recent coverage has focused on Corvus Pharmaceuticals as a high risk, high potential biotech name, with attention on its pipeline and clinical progress as key drivers of sentiment. This context helps explain why the share price has moved so sharply over shorter and longer time frames.

Even after all that, Corvus holds a valuation score of 2 out of 6. Next we will look at how different valuation approaches frame that number and finish with a way of thinking about value that goes beyond any single metric.

Corvus Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corvus Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a business might generate in the future and discounts those cash flows back to today, to arrive at an implied value per share in today’s dollars.

For Corvus Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $32.22 million, and analyst projections, combined with Simply Wall St extrapolations, show free cash flows ranging from a projected $51.30 million loss in 2026 to $289.66 million in 2035. Within that path, free cash flow in 2030 is projected at $57.60 million.

Putting those projected cash flows together and discounting them back to today results in an estimated intrinsic value of $55.83 per share. Compared with the recent share price of $18.66, this model suggests the stock is trading at a 66.6% discount to that intrinsic value, which indicates it may be undervalued according to this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corvus Pharmaceuticals is undervalued by 66.6%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

CRVS Discounted Cash Flow as at Feb 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Corvus Pharmaceuticals.

Approach 2: Corvus Pharmaceuticals Price vs Book

For companies where earnings are not yet a reliable guide, the P/B ratio can be a useful way to think about value, because it compares what the market is paying to the net assets on the balance sheet.

Story continues  

In general, higher growth expectations and lower perceived risk can support a higher P/B multiple, while slower growth or higher risk often line up with a lower, more conservative multiple. So there is no single “right” P/B level for every stock, even within the same industry.

Corvus Pharmaceuticals currently trades on a P/B of 21.78x. That sits well above the Biotechs industry average of 2.62x and the peer group average of 3.80x, so on simple comparisons the shares look expensive relative to book value.

Simply Wall St’s Fair Ratio is a proprietary estimate of what a company’s P/B multiple might be given its growth profile, profit margins, risk factors, industry and market cap. This tends to be more tailored than a basic peer or industry check, which can miss differences in balance sheet strength, business stage or risk.

In Corvus Pharmaceuticals’ case, there is no Fair Ratio available, so it is not possible to say whether the current 21.78x P/B is overvalued, undervalued or about right relative to that model.

Result: ABOUT RIGHT

NasdaqGM:CRVS P/B Ratio as at Feb 2026

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies.

Upgrade Your Decision Making: Choose your Corvus Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company tied directly to your numbers on future revenue, earnings, margins and fair value.

A Narrative helps you connect what you believe about Corvus Pharmaceuticals’ pipeline, risks and opportunities to a clear financial forecast, then to your own fair value estimate, instead of relying only on generic ratios.

On Simply Wall St’s Community page, used by millions of investors, Narratives are an easy tool that let you compare your Fair Value to the current share price to help you decide whether you see Corvus as an opportunity or something to watch, and they automatically update when new information like news or earnings arrives.

For example, one Corvus Pharmaceuticals Narrative might see a relatively high fair value based on optimistic assumptions for future free cash flow, while another might set a much lower fair value with more conservative revenue and margin estimates, and you can see both side by side to decide which story makes more sense to you.

Do you think there’s more to the story for Corvus Pharmaceuticals? Head over to our Community to see what others are saying!

NasdaqGM:CRVS 1-Year Stock Price Chart

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CRVS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info